Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance

Hepatology Research

Volumn 41, Issue 8, 2011, Pages 722-730

  Watanabe, Takao ^a   Konishi, Ichiro ^a   Shigematsu, Shuichiro ^a   Uesugi, Kazuhiro ^a   Joko, Kouji ^c   Seike, Hirotaka ^e   Okada, Shinichi ^f   Miyaoka, Hiroaki ^d   Nakanishi, Seiji ^g   Abe, Masanori ^a   Matsuura, Bunzo ^a   Michitaka, Kojiro ^b   Horiike, Norio ^h   Hiasa, Yoichi ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c MATSUYAMA RED CROSS HOSPITAL   (Japan)

^d Saiseikai Matsuyama Hospital   (Japan)

^e Uwajima City Hospital   (Japan)

^f Saiseikai Saijo Hospital   (Japan)

^g Ehime Prefectural Imabari Hospital   (Japan)

^h Department of Internal Medicine   (Japan)

Author keywords

Compliance; Drug dose; Hepatitis C virus genotype 2; Pegylated interferon; Ribavirin

Indexed keywords

AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; DEPRESSION; DRUG TOLERABILITY; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT RESPONSE; VIRUS LOAD;

EID: 79960709834     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00816.x     Document Type: Article

References (34)

1. Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect 2002; 4: 1219-25.
2. Simmonds P, Bukh J, Combet C etal. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.
3. Nainan OV, Alter MJ, Kruszon-Moran D etal. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-84.
4. Robertson B, Myers G, Howard C etal. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998; 143: 2493-503.
5. Zeuzem S, Hultcrantz R, Bourliere M etal. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
6. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
7. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
8. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
9. Zeuzem S, Pawlotsky JM, Lukasiewicz E etal. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43: 250-7.
10. Poynard T, Ratziu V, McHutchison J etal. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
11. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-15.
12. Martinez-Bauer E, Crespo J, Romero-Gomez M etal. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 2006; 43: 72-80.
13. Akuta N, Suzuki F, Tsubota A etal. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 2002; 37: 831-6.
14. Konishi I, Horiike N, Hiasa Y etal. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 2007; 37: 331-6.
15. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-80.
16. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
17. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
18. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139 (1): 120-9.
19. Akuta N, Suzuki F, Hirakawa M etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Intervirology 2009; 52: 301-9.
20. Inoue Y, Hiramatsu N, Oze T etal. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat 2009; 17: 336-44.
21. Furusyo N, Kajiwara E, Takahashi K etal. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol 2008; 23: 1094-104.
22. McHutchison JG, Manns M, Patel K etal. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
23. Ferenci P, Fried MW, Shiffman ML etal. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-33.
24. Desmet VJ, Gerber M, Hoofnagle JH etal. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
25. Rodriguez-Torres M, Sulkowski MS, Chung RT etal. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 2010; 17: 139-47.
26. Ferenci P, Brunner H, Laferl H etal. A randomized, prospective trial of ribavirin 400mg/day versus 800mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008; 47: 1816-23.
27. Hiramatsu N, Kurashige N, Oze T etal. Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatol Res 2008; 38: 52-9.
28. Ferenci P, Laferl H, Scherzer TM etal. Peginterferon alfa-2a and ribavirin for 24weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.
29. Jensen DM, Morgan TR, Marcellin P etal. Early identification of HCV genotype 1 patients responding to 24weeks peginterferon alpha-2a (40kd)/ribavirin therapy. Hepatology 2006; 43: 954-60.
30. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
31. Kawaoka A, Hayes CN, Ohishi W etal. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotype 2a and 2b. J Hepatol 2010; 54: 408-14.
32. Mangia A, Santoro R, Minerva N etal. Peginterferon alfa-2b and ribavirin for 12 vs. 24weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
33. Dalgard O, Bjoro K, Ring-Larsen H etal. Pegylated interferon alfa and ribavirin for 14 versus 24weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42.
34. Shiffman ML, Suter F, Bacon BR etal. Peginterferon alfa-2a and ribavirin for 16 or 24weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.